← All trials
NCT04941261
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2021
- Primary completion
- Mar 30, 2022
- Completion date
- Sep 30, 2023
- First posted
- Jun 28, 2021
- Last posted
- Jul 6, 2021
- Enrollment
- 1716
- Arms / groups
- 15 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Vaccine and Serum Institute, ChinaLead sponsor
- Zhengzhou UniversityCollaborator
- China National Biotec Group Co., LtdCollaborator
- Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.